Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
The Chinese government offers advanced infrastructure facilities to foreign investors. In addition, easy availability of cheap labor contributes to the expansion of market players in this country. The focus of major market players on China is likely to aid market growth over the forecast period. Increasing initiatives undertaken by market players to develop new treatment options for brain cancer are expected to propel the market growth in the country.
In 2018, GBM accounted for 17% of newly diagnosed brain and nervous system cancers in China, as reported by WHO. I-Mab, a Chinese company, is developing a novel long-acting recombinant human interleukin-7 (rhIL-7), for GBM treatment in China. Moreover, CANbridge Life Sciences’ IND application for a Phase II/III clinical study of lead candidate, CAN008, was approved by China FDA. The clinical trial will evaluate safety and efficacy of weekly CAN008 + re-radiation therapy (rRT) in GBM patients.
Horizon Databook provides a detailed overview of country-level data and insights on the China glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into China glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account